Promising preliminary results have been described in the evaluation of PSMA-expressing prostate cancer [20], but also in breast cancer [17], head and neck cancer [18], pancreatic adenocarcinoma [19] and neuroendocrine tumors [20]. This evidence concerns the gene FOLH1 and head and neck cancer.